Journal of the National Cancer Center最新文献

{"title":"Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review","authors":"Yi Dong ,&nbsp;Liaqat Khan ,&nbsp;Yi Yao","doi":"10.1016/j.jncc.2024.06.004","DOIUrl":"10.1016/j.jncc.2024.06.004","url":null,"abstract":"<div><div>Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC). However, targeted therapy remains the preferred treatment for advanced driver-positive NSCLC, including cases with epidermal growth factor receptor (EGFR) mutations. Considering the variability in EGFR-mutant NSCLC, including expression levels of programmed cell death ligand 1 (PD-L1), tumor mutation burden (TMB), and other immunological features, the application of immunotherapy in this group is still a subject of investigation. Therefore, we have summarized and analyzed the immunological characteristics and regulatory mechanisms of different EGFR mutations in NSCLC, as well as the current clinical application of immunotherapy in the EGFR-mutant population, to provide a reference for future research.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 289-298"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoimmunology in bone malignancies: a symphony with evil","authors":"Churui Song ,&nbsp;Tie Tong ,&nbsp;Biqi Dai ,&nbsp;Yue Zhu ,&nbsp;Elina Chen ,&nbsp;Min Zhang ,&nbsp;Weijie Zhang","doi":"10.1016/j.jncc.2024.09.001","DOIUrl":"10.1016/j.jncc.2024.09.001","url":null,"abstract":"<div><div>Bone marrow is pivotal for normal hematopoiesis and immune responses, yet it is often compromised by malignancies. The bone microenvironment (BME), composed of bone and immune cells, maintains skeletal integrity and blood production. The emergence of primary or metastatic tumors in the skeletal system results in severe complications and contributes significantly to cancer-related mortality. These tumors set off a series of interactions among cancer, bone, and immune cells, and disrupt the BME locally or distantly. However, the drivers, participants, and underlying molecules of these interactions are not fully understood. This review explores the crosstalk between bone metabolism and immune responses, synthesizing current knowledge on the intersection of cancer and osteoimmune biology. It outlines how bone marrow immune cells can either facilitate or hinder tumor progression by interacting with bone cells and pinpoints the molecules responsible for immunosuppression within bone tumors. Moreover, it discusses how primary tumors remotely alter the BME, leading to systemic immune suppression in cancer patients. This knowledge provides critical rationales for emerging immunotherapies in the treatment of bone-related tumors. Taken together, by summarizing the intricate relationship between tumor cells and the BME, this review aims to deepen the understanding of the diversity, complexity, and dynamics at play during bone tumor progression. Ultimately, it highlights the potential of targeting bone-tumor interactions to correct aberrant immune functions, thereby inhibiting tumor growth and metastasis.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 354-368"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori eradication for primary prevention of gastric cancer: progresses and challenges","authors":"Zongchao Liu ,&nbsp;Hengmin Xu ,&nbsp;Weicheng You ,&nbsp;Kaifeng Pan ,&nbsp;Wenqing Li","doi":"10.1016/j.jncc.2024.06.006","DOIUrl":"10.1016/j.jncc.2024.06.006","url":null,"abstract":"<div><div>Gastric cancer remains a significant global health challenge, causing a substantial number of cancer-related deaths, particularly in China. While the exact causes of gastric cancer are still being investigated, <em>Helicobacter pylori</em> (<em>H. pylori</em>) infection has been identified as the primary risk factor, which triggers chronic inflammation and a multistage progression of gastric lesions that may lead to carcinogenesis over a long latency time. Since the 1990s, numerous efforts have focused on assessing the effectiveness of <em>H. pylori</em> eradication in preventing new cases of gastric cancer among both the general population and patients who have undergone early-stage cancer treatment. This body of work, including several community-based interventions and meta-analyses, has shown a reduction in both the incidence of and mortality from gastric cancer following <em>H. pylori</em> treatment, alongside a decreased risk of metachronous gastric cancer. In this review, we seek to consolidate current knowledge on the effects of <em>H. pylori</em> treatment on gastric cancer prevention, its systemic consequences, cost-effectiveness, and the influence of antibiotic resistance and host characteristics on treatment outcomes. We further discuss the potential for precision primary prevention of <em>H. pylori</em> treatment and comment on the efficient implementation of test-and-treat policies and allocation of health resources towards minimizing the burden of gastric cancer globally.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 299-310"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TDERS, an exosome RNA-derived signature predicts prognosis and immunotherapeutic response in clear cell renal cell cancer: a multicohort study","authors":"Aimin Jiang ,&nbsp;Ying Liu ,&nbsp;Ziwei He ,&nbsp;Wenqiang Liu ,&nbsp;Qiwei Yang ,&nbsp;Yu Fang ,&nbsp;Baohua Zhu ,&nbsp;Xiaofeng Wu ,&nbsp;Huamao Ye ,&nbsp;Bicheng Ye ,&nbsp;Shunxiang Gao ,&nbsp;Le Qu ,&nbsp;Wenhao Xu ,&nbsp;Peng Luo ,&nbsp;Linhui Wang","doi":"10.1016/j.jncc.2024.07.002","DOIUrl":"10.1016/j.jncc.2024.07.002","url":null,"abstract":"<div><h3>Background</h3><div>Tumor-derived exosomes are involved in tumor progression and immune invasion and might function as promising noninvasive approaches for clinical management. However, there are few reports on exosom-based markers for predicting the progression and adjuvant therapy response rate among patients with clear cell renal cell carcinoma (ccRCC).</div></div><div><h3>Methods</h3><div>The signatures differentially expressed in exosomes from tumor and normal tissues from ccRCC patients were correspondingly deregulated in ccRCC tissues. We adopted a two-step strategy, including Lasso and bootstrapping, to construct a novel risk stratification system termed the TDERS (Tumor-Derived Exosome-Related Risk Score). During the testing and validation phases, we leveraged multiple external datasets containing over 2000 RCC cases from eight cohorts and one inhouse cohort to evaluate the accuracy of the TDERS. In addition, enrichment analysis, immune infiltration signatures, mutation landscape and therapy sensitivity between the high and low TDERS groups were compared. Finally, the impact of TDERS on the tumor microenvironment (TME) was also analysed in our single-cell datasets.</div></div><div><h3>Results</h3><div>TDERS consisted of 12 mRNAs deregulated in both exosomes and tissues from patients with ccRCC. TDERS achieved satisfactory performance in both prognosis and immune checkpoint inhibitor (ICI) response across all ccRCC cohorts and other pathological types, since the average area under the curve (AUC) to predict 5-year overall survival (OS) was larger than 0.8 across the four cohorts. Patients in the TDERS high group were resistant to ICIs, while mercaptopurine might function as a promising agent for those patients. Patients with a high TDERS were characterized by coagulation and hypoxia, which induced hampered tumor antigen presentation and relative resistance to ICIs. In addition, single cells from 12 advanced samples validated this phenomenon since the interaction between dendritic cells and macrophages was limited. Finally, PLOD2, which is highly expressed in fibro- and epi‑tissue, could be a potential therapeutic target for ccRCC patients since inhibiting PLOD2 altered the malignant phenotype of ccRCC <em>in vitro</em>.</div></div><div><h3>Conclusion</h3><div>As a novel, non-invasive, and repeatable monitoring tool, the TDERS could work as a robust risk stratification system for patients with ccRCC and precisely inform treatment decisions about ICI therapy.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 382-394"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer survival statistics in China 2019–2021: a multicenter, population-based study","authors":"Hongmei Zeng ,&nbsp;Rongshou Zheng ,&nbsp;Kexin Sun ,&nbsp;Maigeng Zhou ,&nbsp;Shaoming Wang ,&nbsp;Li Li ,&nbsp;Ru Chen ,&nbsp;Bingfeng Han ,&nbsp;Meicen Liu ,&nbsp;Jinhui Zhou ,&nbsp;Mengyuan Xu ,&nbsp;Lijun Wang ,&nbsp;Peng Yin ,&nbsp;Baohua Wang ,&nbsp;Jinling You ,&nbsp;Jing Wu ,&nbsp;Wenqiang Wei ,&nbsp;Jie He","doi":"10.1016/j.jncc.2024.06.005","DOIUrl":"10.1016/j.jncc.2024.06.005","url":null,"abstract":"<div><h3>Background</h3><p>A milestone goal of the Healthy China Program (2019–2030) is to achieve 5-year cancer survival at 43.3% for all cancers combined by 2022. To assess the progress towards this target, we analyzed the updated survival for all cancers combined and 25 specific cancer types in China from 2019 to 2021.</p></div><div><h3>Methods</h3><p>We conducted standardized data collection and quality control for cancer registries across 32 provincial-level regions in China, and included 6,410,940 newly diagnosed cancer patients from 281 cancer registries during 2008–2019, with follow-up data on vital status available until December 2021. We estimated the age-standardized 5-year relative survival overall and by site, age group, and period of diagnosis using the International Cancer Survival Standard Weights, and quantified the survival changes to assess the progress in cancer control.</p></div><div><h3>Results</h3><p>In 2019–2021, the age-standardized 5-year relative survival for all cancers combined was 43.7% (95% confidence interval [CI], 43.6–43.7). The 5-year relative survival varied by cancer type, ranging from 8.5% (95% CI, 8.2–8.7) for pancreatic cancer to 92.9% (95% CI, 92.4–93.3) for thyroid cancer. Eight cancers had 5-year survival of over 60%, including cancers of the thyroid, breast, testis, bladder, prostate, kidney, uterus, and cervix. The 5-year relative survival was generally lower in males than in females. From 2008 to 2021, we observed significant survival improvements for cancers of the lung, prostate, bone, uterus, breast, cervix, nasopharynx, larynx, and bladder. The most significant improvement was in lung cancer.</p></div><div><h3>Conclusions</h3><p>Progress in cancer control was evident in China. This highlights the importance of a comprehensive approach to control and prevent cancer.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 203-213"},"PeriodicalIF":7.6,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000498/pdfft?md5=ba2f3e91467cd2db70ca6f11e93b38c3&pid=1-s2.0-S2667005424000498-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between blood glucose and early- and late-onset colorectal cancer: evidence from two prospective cohorts and Mendelian randomization analyses","authors":"Chenyu Luo ,&nbsp;Jiahui Luo ,&nbsp;Yuhan Zhang ,&nbsp;Bin Lu ,&nbsp;Na Li ,&nbsp;Yueyang Zhou ,&nbsp;Shuohua Chen ,&nbsp;Shouling Wu ,&nbsp;Qingsong Zhang ,&nbsp;Min Dai ,&nbsp;Hongda Chen","doi":"10.1016/j.jncc.2024.04.006","DOIUrl":"10.1016/j.jncc.2024.04.006","url":null,"abstract":"<div><h3>Background</h3><p>The incidence of early-onset colorectal cancer (EOCRC), which exhibits differential clinical, pathological, and molecular features compared to late-onset CRC (LOCRC), is rising globally. The potential differential effects of blood glucose on EOCRC compared to LOCRC have not been investigated.</p></div><div><h3>Methods</h3><p>This study analyzed 374,568 participants from the UK Biobank cohort and 172,809 participants from the Kailuan cohort. The linear associations between blood glucose and EOCRC/LOCRC were estimated using Cox regression models. Restricted cubic spline (RCS) analysis and non-linear Mendelian randomization (MR) analysis using a 70-SNPs genetic instrument for fasting glucose were used to explore the potential non-linear associations.</p></div><div><h3>Results</h3><p>Participants in the highest quintile of blood glucose had higher overall CRC risk compared to the lowest quintile (HR = 1.10 in the UK Biobank cohort, 95% CI: 1.01–1.21, <em>P</em>-trend = 0.012; HR = 1.23 in the Kailuan cohort, 95% CI: 1.01–1.51, <em>P</em>-trend = 0.036). Elevated glucose (&gt;7.0 mmol/L) was more strongly associated with increased risk of EOCRC (HR = 1.61, 95% CI: 1.07–2.44) than with LOCRC (HR = 1.14, 95% CI: 1.02–1.27) in the UK Biobank cohort (<em>P-</em>heterogeneity = 0.014). Elevated glucose (&gt;7.0 mmol/L) was associated with increased risk of LOCRC (HR = 1.25, 95% CI: 1.04–1.65) in the Kailuan cohort as well. There was no evidence for non-linear associations between blood glucose and risks of EOCRC/LOCRC.</p></div><div><h3>Conclusions</h3><p>This study showed a positive association between blood glucose and CRC risk in a dose-response manner, particularly for EOCRC, suggesting that tighter glucose control should be a priority for younger age groups.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 241-248"},"PeriodicalIF":7.6,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000486/pdfft?md5=972b697a869f545991a79c7ca79d5b77&pid=1-s2.0-S2667005424000486-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DCS, a novel classifier system based on disulfidptosis reveals tumor microenvironment heterogeneity and guides frontline therapy for clear cell renal carcinoma","authors":"Aimin Jiang ,&nbsp;Wenqiang Liu ,&nbsp;Ying Liu ,&nbsp;Junyi Hu ,&nbsp;Baohua Zhu ,&nbsp;Yu Fang ,&nbsp;Xuenan Zhao ,&nbsp;Le Qu ,&nbsp;Juan Lu ,&nbsp;Bing Liu ,&nbsp;Lin Qi ,&nbsp;Chen Cai ,&nbsp;Peng Luo ,&nbsp;Linhui Wang","doi":"10.1016/j.jncc.2024.06.003","DOIUrl":"10.1016/j.jncc.2024.06.003","url":null,"abstract":"<div><h3>Background</h3><p>Emerging evidence suggests that cell deaths are involved in tumorigenesis and progression, which may be treated as a novel direction of cancers. Recently, a novel type of programmed cell death, disulfidptosis, was discovered. However, the detailed biological and clinical impact of disulfidptosis and related regulators remains largely unknown.</p></div><div><h3>Methods</h3><p>In this work, we first enrolled pancancer datasets and performed multi-omics analysis, including gene expression, DNA methylation, copy number variation and single nucleic variation profiles. Then we deciphered the biological implication of disulfidptosis in clear cell renal cell carcinoma (ccRCC) by machine learning. Finally, a novel agent targeting at disulfidptosis in ccRCC was identified and verified.</p></div><div><h3>Results</h3><p>We found that disulfidptosis regulators were dysregulated among cancers, which could be explained by aberrant DNA methylation and genomic mutation events. Disulfidptosis scores were depressed among cancers and negatively correlated with epithelial mesenchymal transition. Disulfidptosis regulators could satisfactorily stratify risk subgroups in ccRCC, and a novel subtype, DCS3, owning with disulfidptosis depression, insensitivity to immune therapy and aberrant genome instability were identified and verified. Moreover, treating DCS3 with NU1025 could significantly inhibit ccRCC malignancy.</p></div><div><h3>Conclusion</h3><p>This work provided a better understanding of disulfidptosis in cancers and new insights into individual management based on disulfidptosis.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 263-279"},"PeriodicalIF":7.6,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000462/pdfft?md5=b8b27d1b2e48460f1252ccf7d557b9d2&pid=1-s2.0-S2667005424000462-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary liver cancer organoids and their application to research and therapy","authors":"Xiaobin Zhu,&nbsp;Rajiv Trehan,&nbsp;Changqing Xie","doi":"10.1016/j.jncc.2024.06.002","DOIUrl":"10.1016/j.jncc.2024.06.002","url":null,"abstract":"<div><p>Primary liver cancer is a leading cause of death worldwide. To create advanced treatments for primary liver cancer, studies have utilized models such as 2D cell culture and <em>in vivo</em> animal models. Recent developments in cancer organoids have created the possibility for 3D <em>in vitro</em> cultures that recapitulates the cancer cell structure and operation as well as the tumor microenvironment (TME)<em>.</em> However, before organoids can be directly translated to clinical use, tissue processing and culture medium must be standardized with unified protocols to decrease variability in results. Herein, we present the wide variety of published methodologies used to derive liver cancer organoids from patient tumor tissues. Additionally, we summarize validation methodologies for organoids in terms of marker expression levels with immunohistochemistry as well as the presence of mutations and variants through RNA-sequencing. Primary liver cancer organoids have exciting applications allowing for faster drug testing at a larger scale. Primary liver cancer organoids also assisit in uncovering new mechanisms. Through the coculture of different immune cells and cancer organoids, organoids are now better able to recapitulate the liver cancer TME. In addition, it further aids in the investigation of drug development and drug resistance. Lastly, we posit that the usage of liver cancer organoids in animal models provides researchers a methodology to overcome the current limitations of culture systems.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 195-202"},"PeriodicalIF":7.6,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000450/pdfft?md5=71d57bff340d848aa3d9e6fef9dac00e&pid=1-s2.0-S2667005424000450-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Survival Quilts for prognosis prediction of gastrectomy patients based on the Surveillance, Epidemiology, and End Results database and China National Cancer Center Gastric Cancer database","authors":"Lulu Zhao ,&nbsp;Penghui Niu ,&nbsp;Wanqing Wang ,&nbsp;Xue Han ,&nbsp;Xiaoyi Luan ,&nbsp;Huang Huang ,&nbsp;Yawei Zhang ,&nbsp;Dongbing Zhao ,&nbsp;Jidong Gao ,&nbsp;Yingtai Chen","doi":"10.1016/j.jncc.2024.01.007","DOIUrl":"10.1016/j.jncc.2024.01.007","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;Accurate prognosis prediction is critical for individualized-therapy making of gastric cancer patients. We aimed to develop and test 6-month, 1-, 2-, 3-, 5-, and 10-year overall survival (OS) and cancer-specific survival (CSS) prediction models for gastric cancer patients following gastrectomy.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;We derived and tested Survival Quilts, a machine learning-based model, to develop 6-month, 1-, 2-, 3-, 5-, and 10-year OS and CSS prediction models. Gastrectomy patients in the development set (&lt;em&gt;n&lt;/em&gt; = 20,583) and the internal validation set (&lt;em&gt;n&lt;/em&gt; = 5,106) were recruited from the Surveillance, Epidemiology, and End Results (SEER) database, while those in the external validation set (&lt;em&gt;n&lt;/em&gt; = 6,352) were recruited from the China National Cancer Center Gastric Cancer (NCCGC) database. Furthermore, we selected gastrectomy patients without neoadjuvant therapy as a subgroup to train and test the prognostic models in order to keep the accuracy of tumor-node-metastasis (TNM) stage. Prognostic performances of these OS and CSS models were assessed using the Concordance Index (C-index) and area under the curve (AUC) values.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;The machine learning model had a consistently high accuracy in predicting 6-month, 1-, 2-, 3-, 5-, and 10-year OS in the SEER development set (C-index = 0.861, 0.832, 0.789, 0.766, 0.740, and 0.709; AUC = 0.784, 0.828, 0.840, 0.849, 0.869, and 0.902, respectively), SEER validation set (C-index = 0.782, 0.739, 0.712, 0.698, 0.681, and 0.660; AUC = 0.751, 0.772, 0.767, 0.762, 0.766, and 0.787, respectively), and NCCGC set (C-index = 0.691, 0.756, 0.751, 0.737, 0.722, and 0.701; AUC = 0.769, 0.788, 0.790, 0.790, 0.787, and 0.788, respectively). The model was able to predict 6-month, 1-, 2-, 3-, 5-, and 10-year CSS in the SEER development set (C-index = 0.879, 0.858, 0.820, 0.802, 0.784, and 0.774; AUC = 0.756, 0.827, 0.852, 0.863, 0.874, and 0.884, respectively) and SEER validation set (C-index = 0.790, 0.763, 0.741, 0.729, 0.718, and 0.708; AUC = 0.706, 0.758, 0.767, 0.766, 0.766, and 0.764, respectively). In multivariate analysis, the high-risk group with risk score output by 5-year OS model was proved to be a strong survival predictor both in the SEER development set (hazard ratio [HR] = 14.59, 95% confidence interval [CI]: 1.872–2.774, &lt;em&gt;P&lt;/em&gt; &lt; 0.001), SEER validation set (HR = 2.28, 95% CI: 13.089–16.293, &lt;em&gt;P&lt;/em&gt; &lt; 0.001), and NCCGC set (HR = 1.98, 95% CI: 1.617–2.437, &lt;em&gt;P&lt;/em&gt; &lt;em&gt;&lt;&lt;/em&gt; 0.001). We further explored the prognostic value of risk score resulted 5-year CSS model of gastrectomy patients, and found that high-risk group remained as an independent CSS factor in the SEER development set (HR = 12.81, 95% CI: 11.568–14.194, &lt;em&gt;P&lt;/em&gt; &lt; 0.001) and SEER validation set (HR = 1.61, 95% CI: 1.338–1.935, &lt;em&gt;P&lt;/em&gt; &lt; 0.001).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Survival Quilts could allow accurate prediction of 6-m","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 2","pages":"Pages 142-152"},"PeriodicalIF":7.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266700542400019X/pdfft?md5=03ed90ba842276e402ae3a9c6f81bd5f&pid=1-s2.0-S266700542400019X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140270218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic role of circulating tumor DNA across breast cancer molecular subtypes: A systematic review and meta-analysis","authors":"Nana Guo ,&nbsp;Qingxin Zhou ,&nbsp;Meng Zhang ,&nbsp;Xiaowei Chen ,&nbsp;Baoqi Zeng ,&nbsp;Shanshan Wu ,&nbsp;Hongmei Zeng ,&nbsp;Mopei Wang ,&nbsp;Fei Ma ,&nbsp;Feng Sun","doi":"10.1016/j.jncc.2024.04.005","DOIUrl":"10.1016/j.jncc.2024.04.005","url":null,"abstract":"<div><h3>Objective</h3><p>Circulating tumor DNA (ctDNA) is increasingly being used as a potential prognostic biomarker in cancer patients. We aimed to assess the prognostic value of ctDNA in different subtypes of breast cancer patients throughout the whole treatment cycle.</p></div><div><h3>Materials and methods</h3><p>PubMed, Web of Science, Embase, Cochrane Library, Scopus, and clinical trials.gov databases were searched from January 2016 to May 2022. The following search terms were used: ctDNA OR circulating tumor DNA AND breast cancer OR breast carcinoma. Only studies written in English were included. The following pre-specified criteria should be met for inclusion: (i) original articles, conference abstracts, etc.; (ii) patients with breast cancer; (iii) ctDNA measurement; and (iv) clinical outcome data such as recurrence-free survival (RFS) and overall survival (OS). The random-effects model was preferred considering the potential heterogeneity across studies. The main outcomes are ctDNA detection rate and postoperative long-term outcomes (RFS and OS).</p></div><div><h3>Results</h3><p>A total of 24 studies were screened. At every measurement time, the ctDNA detection rate of the HR+ subgroup was similar to that of the HR- subgroup (<em>P</em> = 0.075; <em>P</em> = 0.458; <em>P</em> = 0.744; and <em>P</em> = 0.578), and the ctDNA detection rate of the HER2+ subgroup was similar to that of the HER2- subgroup (<em>P</em> = 0.805; <em>P</em> = 0.271; <em>P</em> = 0.807; and <em>P</em> = 0.703). In the HR+ subgroup, RFS and OS of ctDNA positive patients were similar to those of ctDNA negative patients (<em>P</em> = 0.589 and <em>P</em> = 0.110), while RFS and OS of the ctDNA positive group was significantly shorter than those of the ctDNA negative patients in the HR- subgroup (HR = 4.03, <em>P</em> &lt; 0.001; HR = 3.21, <em>P</em> &lt; 0.001). According to HER grouping, the results were the same as above. In the triple negative breast cancer (TNBC) subgroup, the RFS and OS of ctDNA-positive patients was significantly shorter than of the ctDNA negative patients before and after surgery.</p></div><div><h3>Conclusions</h3><p>ctDNA was more predictive of recurrence-free survival and overall survival in the HR- subgroup than in the HR+ subgroup, and the same result was showed in the HER2- subgroup <em>vs</em>. HER2+ subgroup. The prognosis of the TNBC subtype is closely related to ctDNA before and after surgery.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 2","pages":"Pages 153-161"},"PeriodicalIF":7.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000267/pdfft?md5=fd31fa5ddae7c55667f1411404631dd6&pid=1-s2.0-S2667005424000267-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}